Chemistry:GYKI-52895

GYKI-52895

Clinical data
Other names	4-(8,9-Dihydro-8-methyl-7H-1,3-dioxolo[4,5-h][2,3]benzodiazepin-5-yl)benzenamine
Identifiers
IUPAC name 4-{13-methyl-4,6-dioxa-11,12-diazatricyclo[7.5.0.03,7]tetradeca-1,3(7),8,10-tetraen-10-yl}aniline
CAS Number	869360-93-0 Y
PubChem CID	3539
ChemSpider	3418 Y
KEGG	C15094 Y
Chemical and physical data
Formula	C17H17N3O2
Molar mass	295.342 g·mol−1
3D model (JSmol)	Interactive image
SMILES O1c2c(OC1)cc3c(c2)C(=N/NC(C3)C)\c4ccc(N)cc4
InChI InChI=1S/C17H17N3O2/c1-10-6-12-7-15-16(22-9-21-15)8-14(12)17(20-19-10)11-2-4-13(18)5-3-11/h2-5,7-8,10,19H,6,9,18H2,1H3 Y Key:AQTITSBNGSVQNZ-UHFFFAOYSA-N Y
(verify)

GYKI-52895 is a drug which is a 2,3-benzodiazepine derivative that also shares the 3,4-Methylenedioxyphenethylamine pharmacophore. Unlike other similar drugs, GYKI-52895 is a selective dopamine reuptake inhibitor (DARI), which appears to have an atypical mode of action compared to other DARIs. Its DRI activity is shared by numerous addictive drugs including amphetamine and its derivatives (e.g. dextromethamphetamine), cocaine, and methylphenidate and its derivatives (e.g. ethylphenidate). However, dopaminergic drugs are also prone to producing emetic effects such as in the case of apomorphine.

See also

• GYKI-52,466, another 2,3-benzodiazepine with other than GABAergic function
• Tifluadom
• Lufuradom
• Benzodiazepine
• Substituted methylenedioxyphenethylamine